APA (7th ed.) Citation

S, C., D, C., P, H., C, C., K, L., A, T., . . . A, S. (2025). Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation. Alimentary pharmacology & therapeutics, 62(10), 1003. https://doi.org/10.1111/apt.70283

Chicago Style (17th ed.) Citation

S, Chin, Con D, Hilley P, Corte C, Liu K, Testro A, De Cruz P, Choy MC, and Srinivasan A. "Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation." Alimentary Pharmacology & Therapeutics 62, no. 10 (2025): 1003. https://doi.org/10.1111/apt.70283.

MLA (9th ed.) Citation

S, Chin, et al. "Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation." Alimentary Pharmacology & Therapeutics, vol. 62, no. 10, 2025, p. 1003, https://doi.org/10.1111/apt.70283.